Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 7, 2015, Pages 1658-1671

  Correia, Cristina ^a,b   Lee, Sun Hee ^a,b   Meng, X Wei ^a,b   Vincelette, Nicole D ^b   Knorr, Katherine L B ^b   Ding, Husheng ^a   Nowakowski, Grzegorz S ^a   Dai, Haiming ^a,b   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Activation induced cytidine deaminase; Apoptosis; BH3 mimetic; Follicular lymphoma; Mutation

Indexed keywords

PROTEIN BCL 2;

AMINO ACID SEQUENCE; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CHEMISTRY; DISEASE COURSE; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84928332593     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.03.012     Document Type: Review

References (282)

1. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
2. Meng X.W., Lee S.H., Kaufmann S.H. Apoptosis in the treatment of cancer: a promise kept?. Curr. Opin. Cell Biol. 2006, 18:668-676.
3. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9:231-241.
4. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu. Rev. Biochem. 1999, 68:383-424.
5. van Delft M.F., Huang D.C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 2006, 2:203-213.
6. Wang C., Youle R.J. The role of mitochondria in apoptosis. Ann. Rev. Genet. 2009, 43:95-118.
7. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. Cell 1996, 86:147-157.
8. Jiang X., Wang X. Cytochrome C-mediated apoptosis. Annu. Rev. Biochem. 2004, 73:87-106.
9. Strasser A., Cory S., Adams J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011, 30:3667-3683.
10. Czabotar P.E., Lessene G., Strasser A., Adams J.M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 2014, 15:49-63.
11. Moldoveanu T., Follis A.V., Kriwacki R.W., Green D.R. Many players in BCL-2 family affairs. Trends Biochem. Sci. 2014, 39:101-111.
12. Renault T.T., Chipuk J.E. Death upon a kiss: mitochondrial outer membrane composition and organelle communication govern sensitivity to BAK/BAX-dependent apoptosis. Chem. Biol. 2014, 21:114-123.
13. Ekert P.G., Vaux D.L. The mitochondrial death squad - hardened killers or innocent bystanders?. Curr. Opin. Cell Biol. 2005, 17:626-630.
14. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell 2011, 21:92-101.
15. Hyman B.T., Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat. Rev. Neurosci. 2012, 13:395-406.
16. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
17. Tsujimoto Y., Cossman J., Jaffe E., Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443.
18. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., Mc Henry K.T., Pinchback R.M., Ligon A.H., Cho Y.J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J., Liefeld T., Gao Q., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M.S., Demichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
19. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969.
20. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.J., Wheat L.M., Karran E.L., Garcia J.F., Sanchez L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J., Martinez-Climent J.A. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007, 109:271-280.
21. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
22. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
23. Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 2001, 15:1481-1486.
24. Wang K., Gross A., Waksman G., Korsmeyer S.J. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol. Cell. Biol. 1998, 18:6083-6089.
25. Dewson G., Kratina T., Sim H.W., Puthalakath H., Adams J.M., Colman P.M., Kluck R.M. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol. Cell 2008, 30:369-380.
26. Dewson G., Kratina T., Czabotar P., Day C.L., Adams J.M., Kluck R.M. Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. Mol. Cell 2009, 36:696-703.
27. Ma S., Hockings C., Anwari K., Kratina T., Fennell S., Lazarou M., Ryan M.T., Kluck R.M., Dewson G. Assembly of the Bak apoptotic pore: a critical role for the Bak protein alpha6 helix in the multimerization of homodimers during apoptosis. J. Biol. Chem. 2013, 288:26027-26038.
28. Pang Y.P., Dai H., Smith A., Meng X.W., Schneider P.A., Kaufmann S.H. Bak conformational changes induced by ligand binding: insight into BH3 domain binding and Bak homo-oligomerization. Sci. Rep. 2012, 2:257.
29. Zhang Z., Zhu W., Lapolla S.M., Miao Y., Shao Y., Falcone M., Boreham D., McFarlane N., Ding J., Johnson A.E., Zhang X.C., Andrews D.W., Lin J. Bax forms an oligomer via separate, yet interdependent, surfaces. J. Biol. Chem. 2010, 285:17614-17627.
30. Czabotar P.E., Westphal D., Dewson G., Ma S., Hockings C., Fairlie W.D., Lee E.F., Yao S., Robin A.Y., Smith B.J., Huang D.C., Kluck R.M., Adams J.M., Colman P.M. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 2013, 152:519-531.
31. Brouwer J.M., Westphal D., Dewson G., Robin A.Y., Uren R.T., Bartolo R., Thompson G.V., Colman P.M., Kluck R.M., Czabotar P.E. Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. Mol. Cell 2014, 55:938-946.
32. Willis S.N., Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 2005, 17:617-625.
33. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., Thompson C.B., Korsmeyer S.J. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000, 14:2060-2071.
34. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., Newmeyer D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 2005, 17:525-535.
35. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
36. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., Cheng E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 2006, 8:1348-1358.
37. Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., Tu H.C., Kim H., Cheng E.H., Tjandra N., Walensky L.D. BAX activation is initiated at a novel interaction site. Nature 2008, 455:1076-1081.
38. Dai H., Pang Y.P., Ramirez-Alvarado M., Kaufmann S.H. Evaluation of the BH3-only protein Puma as a direct Bak activator. J. Biol. Chem. 2014, 289:89-99.
39. Dai H., Smith A., Meng X.W., Schneider P.A., Pang Y.P., Kaufmann S.H. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J. Cell Biol. 2011, 194:39-48.
40. Ren D., Tu H.C., Kim H., Wang G.X., Bean G.R., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J., Cheng E.H. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010, 330:1390-1393.
41. Villunger A., Labi V., Bouillet P., Adams J., Strasser A. Can the analysis of BH3-only protein knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak?. Cell Death Differ. 2011, 18:1545-1546.
42. Erlacher M., Labi V., Manzl C., Bock G., Tzankov A., Hacker G., Michalak E., Strasser A., Villunger A. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J. Exp. Med. 2006, 203:2939-2951.
43. Sarosiek K.A., Chi X., Bachman J.A., Sims J.J., Montero J., Patel L., Flanagan A., Andrews D.W., Sorger P., Letai A. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol. Cell 2013, 51:751-765.
44. Du H., Wolf J., Schafer B., Moldoveanu T., Chipuk J.E., Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J. Biol. Chem. 2011, 286:491-501.
45. Moldoveanu T., Grace C.R., Llambi F., Nourse A., Fitzgerald P., Gehring K., Kriwacki R.W., Green D.R. BID-induced structural changes in BAK promote apoptosis. Nat. Struct. Mol. Biol. 2013, 20:589-597.
46. Leshchiner E.S., Braun C.R., Bird G.H., Walensky L.D. Direct activation of full-length proapoptotic BAK. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E986-E995.
47. Gavathiotis E., Reyna D.E., Davis M.L., Bird G.H., Walensky L.D. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol. Cell 2010, 40:481-492.
48. Kim H., Tu H.C., Ren D., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J., Cheng E.H. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 2009, 36:487-499.
49. Walensky L.D., Pitter K., Morash J., Oh K.J., Barbuto S., Fisher J., Smith E., Verdine G.L., Korsmeyer S.J. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell 2006, 24:199-210.
50. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., Ierino H., Lee E.F., Fairlie W.D., Bouillet P., Strasser A., Kluck R.M., Adams J.M., Huang D.C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
51. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 2005, 17:393-403.
52. Llambi F., Moldoveanu T., Tait S.W., Bouchier-Hayes L., Temirov J., McCormick L.L., Dillon C.P., Green D.R. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 2011, 44:517-531.
53. Edwards A.L., Gavathiotis E., LaBelle J.L., Braun C.R., Opoku-Nsiah K.A., Bird G.H., Walensky L.D. Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem. Biol. 2013, 20:888-902.
54. Dai H., Ding H., Meng X.W., Lee S.H., Schneider P.A., Kaufmann S.H. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res. 2013, 73:6998-7008.
55. Lindner A.U., Concannon C.G., Boukes G.J., Cannon M.D., Llambi F., Ryan D., Boland K., Kehoe J., McNamara D.A., Murray F., Kay E.W., Hector S., Green D.R., Huber H.J., Prehn J.H. Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. Cancer Res. 2013, 73:519-528.
56. Weber K., Harper N., Schwabe J., Cohen G.M. BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis. Cell Rep. 2013, 5:409-420.
57. Peng R., Tong J.S., Li H., Yue B., Zou F., Yu J., Zhang L. Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation. Cell Death Differ. 2013, 20:744-754.
58. Vela L., Gonzalo O., Naval J., Marzo I. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. J. Biol. Chem. 2013, 288:4935-4946.
59. Merino D., Giam M., Hughes P.D., Siggs O.M., Heger K., O'Reilly L.A., Adams J.M., Strasser A., Lee E.F., Fairlie W.D., Bouillet P. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J. Cell Biol. 2009, 186:355-362.
60. Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Chang B.S., Thompson C.B., Wong S.L., Ng S.L., Fesik S.W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996, 381:335-341.
61. Suzuki M., Youle R.J., Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000, 103:645-654.
62. Moldoveanu T., Liu Q., Tocilj A., Watson M., Shore G., Gehring K. The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol. Cell 2006, 24:677-688.
63. Choe S., Bennett M.J., Fujii G., Curmi P.M., Kantardjieff K.A., Collier R.J., Eisenberg D. The crystal structure of diphtheria toxin. Nature 1992, 357:216-222.
64. Elkins P., Bunker A., Cramer W.A., Stauffacher C.V. A mechanism for toxin insertion into membranes is suggested by the crystal structure of the channel-forming domain of colicin E1. Structure 1997, 5:443-458.
65. Parker M.W., Feil S.C. Pore-forming protein toxins: from structure to function. Prog. Biophys. Mol. Biol. 2005, 88:91-142.
66. Annis M.G., Soucie E.L., Dlugosz P.J., Cruz-Aguado J.A., Penn L.Z., Leber B., Andrews D.W. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J. 2005, 24:2096-2103.
67. Fuertes G., Garcia-Saez A.J., Esteban-Martin S., Gimenez D., Sanchez-Munoz O.L., Schwille P., Salgado J. Pores formed by Baxalpha5 relax to a smaller size and keep at equilibrium. Biophys. J. 2010, 99:2917-2925.
68. Garcia-Saez A.J., Coraiola M., Serra M.D., Mingarro I., Muller P., Salgado J. Peptides corresponding to helices 5 and 6 of Bax can independently form large lipid pores. FEBS J. 2006, 273:971-981.
69. Qian S., Wang W., Yang L., Huang H.W. Structure of transmembrane pore induced by Bax-derived peptide: evidence for lipidic pores. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17379-17383.
70. Westphal D., Dewson G., Menard M., Frederick P., Iyer S., Bartolo R., Gibson L., Czabotar P.E., Smith B.J., Adams J.M., Kluck R.M. Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4076-E4085.
71. Terrones O., Etxebarria A., Landajuela A., Landeta O., Antonsson B., Basanez G. BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes. J. Biol. Chem. 2008, 283:7790-7803.
72. Landeta O., Landajuela A., Gil D., Taneva S., Di Primo C., Sot B., Valle M., Frolov V.A., Basanez G. Reconstitution of proapoptotic BAK function in liposomes reveals a dual role for mitochondrial lipids in the BAK-driven membrane permeabilization process. J. Biol. Chem. 2011, 286:8213-8230.
73. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
74. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000, 256:42-49.
75. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003, 302:1036-1038.
76. Tan T.T., Degenhardt K., Nelson D.A., Beaudoin B., Nieves-Neira W., Bouillet P., Villunger A., Adams J.M., White E. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005, 7:227-238.
77. Torres K., Horwitz S.B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 1998, 58:3620-3626.
78. Cragg M.S., Jansen E.S., Cook M., Harris C., Strasser A., Scott C.L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 2008, 118:3651-3659.
79. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., Kimura S., Ottmann O.G., Druker B.J., Villunger A., Roberts A.W., Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14907-14912.
80. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999, 17:2941-2953.
81. Gerl R., Vaux D.L. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005, 26:263-270.
82. Kuwana T., Mackey M.R., Perkins G., Ellisman M.H., Latterich M., Schneiter R., Green D.R., Newmeyer D.D. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002, 111:331-342.
83. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
84. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 2007, 117:112-121.
85. Deng J., Carlson N., Takeyama K., Dal Cin P., Shipp M., Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12:171-185.
86. Vo T.T., Ryan J., Carrasco R., Neuberg D., Rossi D.J., Stone R.M., Deangelo D.J., Frattini M.G., Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012, 151:344-355.
87. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore Vdel G., Deng J., Anderson K.C., Richardson P., Tai Y.T., Mitsiades C.S., Matulonis U.A., Drapkin R., Stone R., Deangelo D.J., McConkey D.J., Sallan S.E., Silverman L., Hirsch M.S., Carrasco D.R., Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
88. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., Steele G.D., Chen L.B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3671-3675.
89. Brunelle J.K., Ryan J., Yecies D., Opferman J.T., Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J. Cell Biol. 2009, 187:429-442.
90. Ryan J.A., Brunelle J.K., Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:12895-12900.
91. Pan R., Hogdal L.J., Benito J.M., Bucci D., Han L., Borthakur G., Cortes J., DeAngelo D.J., Debose L., Mu H., Dohner H., Gaidzik V.I., Galinsky I., Golfman L.S., Haferlach T., Harutyunyan K.G., Hu J., Leverson J.D., Marcucci G., Muschen M., Newman R., Park E., Ruvolo P.P., Ruvolo V., Ryan J., Schindela S., Zweidler-McKay P., Stone R.M., Kantarjian H., Andreeff M., Konopleva M., Letai A.G. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014, 4:362-375.
92. Konopleva M., Pollyea D.A., Potluri J., Chyla B.J., Busman T.A., McKeegan E., Salem A., Zhu M., Ricker J.L., Blum W., DiNardo C.D., Dunbar M., Kirby R., Falotico N., Leverson J.D., Humerickhouse R.A., Mabry M., Stone R.M., Kantarjian H.M., Letai A. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood 2014, 124. (Abstract 118).
93. Bakhshi A., Jensen J.P., Goldman P., Wright J.J., McBride O.W., Epstein A.L., Korsmeyer S.J. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41:899-906.
94. Cleary M.L., Smith S.D., Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986, 47:19-28.
95. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335:440-442.
96. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
97. Ko J.K., Choi K.H., Pan Z., Lin P., Weisleder N., Kim C.W., Ma J. The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis. J. Cell Sci. 2007, 120:2912-2923.
98. Brien G., Debaud A.L., Robert X., Oliver L., Trescol-Biemont M.C., Cauquil N., Geneste O., Aghajari N., Vallette F.M., Haser R., Bonnefoy-Berard N. C-terminal residues regulate localization and function of the antiapoptotic protein Bfl-1. J. Biol. Chem. 2009, 284:30257-30263.
99. Hind C.K., Carter M.J., Harris C.L., Chan H.T., James S., Cragg M.S. Role of the pro-survival molecule Bfl-1 in melanoma. Int. J. Biochem. Cell Biol. 2015, 59:94-102.
100. Rautureau G.J., Yabal M., Yang H., Huang D.C., Kvansakul M., Hinds M.G. The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death Dis. 2012, 3:e443.
101. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
102. Simmons M.J., Fan G., Zong W.X., Degenhardt K., White E., Gelinas C. Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 2008, 27:1421-1428.
103. Dai H., Meng X.W., Lee S.H., Schneider P.A., Kaufmann S.H. Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J. Biol. Chem. 2009, 284:18311-18322.
104. Opferman J.T., Iwasaki H., Ong C.C., Suh H., Mizuno S., Akashi K., Korsmeyer S.J. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005, 307:1101-1104.
105. Steimer D.A., Boyd K., Takeuchi O., Fisher J.K., Zambetti G.P., Opferman J.T. Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 2009, 113:2805-2815.
106. Perciavalle R.M., Stewart D.P., Koss B., Lynch J., Milasta S., Bathina M., Temirov J., Cleland M.M., Pelletier S., Schuetz J.D., Youle R.J., Green D.R., Opferman J.T. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat. Cell Biol. 2012, 14:575-583.
107. Glaser S.P., Lee E.F., Trounson E., Bouillet P., Wei A., Fairlie W.D., Izon D.J., Zuber J., Rappaport A.R., Herold M.J., Alexander W., Lowe S.W., Robb L., Strasser A. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012, 26:120-125.
108. Wang X., Bathina M., Lynch J., Koss B., Calabrese C., Frase S., Schuetz J.D., Rehg J.E., Opferman J.T. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013, 27:1351-1364.
109. Sochalska M., Tuzlak S., Egle A., Villunger A. Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J. 2015, 282:834-849.
110. Rooswinkel R.W., van de Kooij B., de Vries E., Paauwe M., Braster R., Verheij M., Borst J. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood 2014, 123:2806-2815.
111. Lowe S.W., Cepro E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
112. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348:331-333.
113. Eischen C.M., Woo D., Roussel M.F., Cleveland J.L. Apoptosis triggered by myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 2001, 21:5063-5070.
114. Fanidi A., Harrington E.A., Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992, 359:554-556.
115. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
116. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008, 111:3322-3330.
117. Scarfo L., Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol. Lett. 2013, 155:36-39.
118. Maung Z.T., MacLean F.R., Reid M.M., Pearson A.D.J., Proctor S.J., Hamilton P.J., Hall A.G. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br. J. Haematol. 1994, 88:105-109.
119. Bincoletto C., Saad S.T., da Silva E.S., Queiroz M.L. Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia. Eur. J. Haematol. 1999, 62:38-42.
120. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., Reed J.C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998, 91:991-1000.
121. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13944-13949.
122. Breitschopf K., Haendeler J., Malchow P., Zeiher A.M., Dimmeler S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell. Biol. 2000, 20:1886-1896.
123. Niture S.K., Jaiswal A.K. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 2012, 287:9873-9886.
124. Niture S.K., Jaiswal A.K. Inhibitor of Nrf2 (INrf2 or Keap1) protein degrades Bcl-xL via phosphoglycerate mutase 5 and controls cellular apoptosis. J. Biol. Chem. 2011, 286:44542-44556.
125. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4507-4511.
126. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996, 56:1253-1255.
127. Blagosklonny M.V., Giannakakou P., el-Deiry W.S., Kingston D.G., Higgs P.I., Neckers L., Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997, 57:130-135.
128. Wei Y., Pattingre S., Sinha S., Bassik M., Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 2008, 30:678-688.
129. Haldar S., Basu A., Croce C.M. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 1998, 58:1609-1615.
130. Furukawa Y., Iwase S., Kikuchi J., Terui Y., Nakamura M., Yamada H., Kano Y., Matsuda M. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J. Biol. Chem. 2000, 275:21661-21667.
131. Maundrell K., Antonsson B., Magnenat E., Camps M., Muda M., Chabert C., Gillieron C., Boschert U., Vial-Knecht E., Martinou J.C., Arkinstall S. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. Biol. Chem. 1997, 272:25238-25242.
132. Srivastava R.K., Mi Q.S., Hardwick J.M., Longo D.L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3775-3780.
133. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., Longo D.L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 1998, 18:3509-3517.
134. De Chiara G., Marcocci M.E., Torcia M., Lucibello M., Rosini P., Bonini P., Higashimoto Y., Damonte G., Armirotti A., Amodei S., Palamara A.T., Russo T., Garaci E., Cozzolino F. Bcl-2 phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J. Biol. Chem. 2006, 281:21353-21361.
135. Ruvolo P.P., Deng X., Carr B.K., May W.S. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 1998, 273:25436-25442.
136. Asnaghi L., Calastretti A., Bevilacqua A., D'Agnano I., Gatti G., Canti G., Delia D., Capaccioli S., Nicolin A. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004, 23:5781-5791.
137. Terrano D.T., Upreti M., Chambers T.C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell. Biol. 2010, 30:640-656.
138. Sakurikar N., Eichhorn J.M., Chambers T.C. Cyclin-dependent kinase-1 (Cdk1)/cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. J. Biol. Chem. 2012, 287:39193-39204.
139. Ling Y.H., Tornos C., Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 1998, 273:18984-18991.
140. Scatena C.D., Stewart Z.A., Mays D., Tang L.J., Keefer C.J., Leach S.D., Pietenpol J.A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem. 1998, 273:30777-30784.
141. Yamamoto K., Ichijo H., Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 1999, 19:8469-8478.
142. Bassik M.C., Scorrano L., Oakes S.A., Pozzan T., Korsmeyer S.J. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J. 2004, 23:1207-1216.
143. Ito T., Deng X., Carr B., May W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 1997, 272:11671-11673.
144. Deng X., Ruvolo P., Carr B., May W.S. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1578-1583.
145. Deng X., Gao F., Flagg T., May W.S. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:153-158.
146. Deng X., Gao F., Flagg T., Anderson J., May W.S. Bcl2's flexible loop domain regulates p53 binding and survival. Mol. Cell. Biol. 2006, 26:4421-4434.
147. Jin Z., Gao F., Flagg T., Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J. Biol. Chem. 2004, 279:40209-40219.
148. Petros A.M., Medek A., Nettesheim D.G., Kim D.H., Yoon H.S., Swift K., Matayoshi E.D., Oltersdorf T., Fesik S.W. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3012-3017.
149. Ku B., Liang C., Jung J.U., Oh B.H. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res. 2011, 21:627-641.
150. Schmitt E., Beauchemin M., Bertrand R. Nuclear colocalization and interaction between bcl-xL and cdk1(cdc2) during G2/M cell-cycle checkpoint. Oncogene 2007, 26:5851-5865.
151. Upreti M., Galitovskaya E.N., Chu R., Tackett A.J., Terrano D.T., Granell S., Chambers T.C. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J. Biol. Chem. 2008, 283:35517-35525.
152. Ding Q., He X., Hsu J.M., Xia W., Chen C.T., Li L.Y., Lee D.F., Liu J.C., Zhong Q., Wang X., Hung M.C. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 2007, 27:4006-4017.
153. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
154. Kobayashi S., Lee S.H., Meng X.W., Mott J.L., Bronk S.F., Werneburg N.W., Craig R.W., Kaufmann S.H., Gores G.J. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J. Biol. Chem. 2007, 282:18407-18417.
155. Jiffar T., Kurinna S., Suck G., Carlson-Bremer D., Ricciardi M.R., Konopleva M., Andreeff M., Ruvolo P.P. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 2004, 18:505-512.
156. Ding Q., Huo L., Yang J.Y., Xia W., Wei Y., Liao Y., Chang C.J., Yang Y., Lai C.C., Lee D.F., Yen C.J., Chen Y.J., Hsu J.M., Kuo H.P., Lin C.Y., Tsai F.J., Li L.Y., Tsai C.H., Hung M.C. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008, 68:6109-6117.
157. Low I.C., Loh T., Huang Y., Virshup D.M., Pervaiz S. Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56delta stabilizes its antiapoptotic activity. Blood 2014, 124:2223-2234.
158. Visco C., Tzankov A., Xu-Monette Z.Y., Miranda R.N., Tai Y.C., Li Y., Liu W.M., d'Amore E.S., Li Y., Montes-Moreno S., Dybkaer K., Chiu A., Orazi A., Zu Y., Bhagat G., Wang H.Y., Dunphy C.H., His E.D., Zhao X.F., Choi W.W., Zhao X., van Krieken J.H., Huang Q., Ai W., O'Neill S., Ponzoni M., Ferreri A.J., Kahl B.S., Winter J.N., Go R.S., Dirnhofer S., Piris M.A., Moller M.B., Wu L., Medeiros L.J., Young K.H. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL Rituximab-CHOP Consortium Program Study. Haematologica 2013, 98:255-263.
159. Tanaka S., Louie D.C., Kant J.A., Reed J.C. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood 1992, 79:229-237.
160. Seto M., Jaeger U., Hockett R.D., Graninger W., Bennett S., Goldman P., Korsmeyer S.J. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988, 7:123-131.
161. Aukema S.M., Siebert R., Schuuring E., van Imhoff G.W., Kluin-Nelemans H.C., Boerma E.J., Kluin P.M. Double-hit B-cell lymphomas. Blood 2011, 117:2319-2331.
162. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., Cruz-Gordillo P., Knoechel B., Asmann Y.W., Slager S.L., Novak A.J., Dogan A., Ansell S.M., Link B.K., Zou L., Gould J., Saksena G., Stransky N., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Hernandez-Lemus E., Schwarz-Cruz y Celis A., Imaz-Rosshandler I., Ojesina A.I., Jung J., Pedamallu C.S., Lander E.S., Habermann T.M., Cerhan J.R., Shipp M.A., Getz G., Golub T.R. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3879-3884.
163. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., Jackman S., Krzywinski M., Scott D.W., Trinh D.L., Tamura-Wells J., Li S., Firme M.R., Rogic S., Griffith M., Chan S., Yakovenko O., Meyer I.M., Zhao E.Y., Smailus D., Moksa M., Chittaranjan S., Rimsza L., Brooks-Wilson A., Spinelli J.J., Ben-Neriah S., Meissner B., Woolcock B., Boyle M., McDonald H., Tam A., Zhao Y., Delaney A., Zeng T., Tse K., Butterfield Y., Birol I., Holt R., Schein J., Horsman D.E., Moore R., Jones S.J., Connors J.M., Hirst M., Gascoyne R.D., Marra M.A. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
164. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., Wells V.A., Grunn A., Messina M., Elliot O., Chan J., Bhagat G., Chadburn A., Gaidano G., Mullighan C.G., Rabadan R., Dalla-Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 2011, 43:830-837.
165. Schuetz J.M., Johnson N.A., Morin R.D., Scott D.W., Tan K., Ben-Nierah S., Boyle M., Slack G.W., Marra M.A., Connors J.M., Brooks-Wilson A.R., Gascoyne R.D. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012, 26:1383-1390.
166. Casulo C., Burack W.R., Friedberg J.W. Transformed follicular non-Hodgkin lymphoma. Blood 2015, 125:40-47.
167. Bernstein S.H., Burack W.R. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am. Soc. Hematol. Educ. Program 2009, 532-541.
168. Montoto S., Fitzgibbon J. Transformation of indolent B-cell lymphomas. J. Clin. Oncol. 2011, 29:1827-1834.
169. Pasqualucci L., Khiabanian H., Fangazio M., Vasishtha M., Messina M., Holmes A.B., Ouillette P., Trifonov V., Rossi D., Tabbo F., Ponzoni M., Chadburn A., Murty V.V., Bhagat G., Gaidano G., Inghirami G., Malek S.N., Rabadan R., Dalla-Favera R. Genetics of follicular lymphoma transformation. Cell Rep. 2014, 6:130-140.
170. Green M.R., Gentles A.J., Nair R.V., Irish J.M., Kihira S., Liu C.L., Kela I., Hopmans E.S., Myklebust J.H., Ji H., Plevritis S.K., Levy R., Alizadeh A.A. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013, 121:1604-1611.
171. Okosun J., Bodor C., Wang J., Araf S., Yang C.Y., Pan C., Boller S., Cittaro D., Bozek M., Iqbal S., Matthews J., Wrench D., Marzec J., Tawana K., Popov N., O'Riain C., O'Shea D., Carlotti E., Davies A., Lawrie C.H., Matolcsy A., Calaminici M., Norton A., Byers R.J., Mein C., Stupka E., Lister T.A., Lenz G., Montoto S., Gribben J.G., Fan Y., Grosschedl R., Chelala C., Fitzgibbon J. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 2014, 46:176-181.
172. Reed J.C., Tanaka S. Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphoGas and lymphocytic leukemias: implications for mechanisms of tumor progression. Leuk. Lymphoma 1993, 10:157-163.
173. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991, 349:254-256.
174. Smith A.J., Dai H., Correia C., Takahashi R., Lee S.H., Schmitz I., Kaufmann S.H. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J. Biol. Chem. 2011, 286:17682-17692.
175. Correia C., Schneider P.A., Dai H., Dogan A., Maurer M.J., Church A.K., Novak A.J., Feldman A.L., Wu X., Ding H., Meng X.W., Cerhan J.R., Slager S.L., Macon W.R., Habermann T.M., Karp J.E., Gore S.D., Kay N.E., Jelinek D.F., Witzig T.E., Nowakowski G.S., Kaufmann S.H. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 2015, 125:658-667.
176. Herman M.D., Nyman T., Welin M., Lehtio L., Flodin S., Tresaugues L., Kotenyova T., Flores A., Nordlund P. Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim. FEBS Lett. 2008, 582:3590-3594.
177. Huang D.C., Adams J.M., Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998, 17:1029-1039.
178. Hirotani M., Zhang Y., Fujita N., Naito M., Tsuruo T. NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis. J. Biol. Chem. 1999, 274:20415-20420.
179. Monaco G., Decrock E., Nuyts K., Wagner L.E., Luyten T., Strelkov S.V., Missiaen L., De Borggraeve W.M., Leybaert L., Yule D.I., De Smedt H., Parys J.B., Bultynck G. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor. PLoS One 2013, 8:e73386.
180. Barclay L.A., Wales T.E., Garner T.P., Wachter F., Lee S., Guerra R.M., Stewart M.L., Braun C.R., Bird G.H., Gavathiotis E., Engen J.R., Walensky L.D. Inhibition of pro-apoptotic BAX by a noncanonical interaction mechanism. Mol. Cell 2015, 57:873-886.
181. Duquette M.L., Huber M.D., Maizels N. G-rich proto-oncogenes are targeted for genomic instability in B-cell lymphomas. Cancer Res. 2007, 67:2586-2594.
182. Friedberg J.W. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin. Hematol. 2008, 45:S2-S6.
183. Link B.K., Maurer M.J., Nowakowski G.S., Ansell S.M., Macon W.R., Syrbu S.I., Slager S.L., Thompson C.A., Inwards D.J., Johnston P.B., Colgan J.P., Witzig T.E., Habermann T.M., Cerhan J.R. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J. Clin. Oncol. 2013, 31:3272-3278.
184. Kitada S., Leone M., Sareth S., Zhai D., Reed J.C., Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 2003, 46:4259-4264.
185. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
186. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 2008, 7:989-1000.
187. Billard C. BH3 mimetics: status of the field and new developments. Mol. Cancer Ther. 2013, 12:1691-1700.
188. Leverson J.D., Zhang H., Chen J., Tahir S.K., Phillips D.C., Xue J., Nimmer P., Jin S., Smith M., Xiao Y., Kovar P., Tanaka A., Bruncko M., Sheppard G.S., Wang L., Gierke S., Kategaya L., Anderson D.J., Wong C., Eastham-Anderson J., Ludlam M.J., Sampath D., Fairbrother W.J., Wertz I., Rosenberg S.H., Tse C., Elmore S.W., Souers A.J. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015, 6:e1590.
189. Belmar J., Fesik S.W. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol. Ther. 2015, 145:76-84.
190. Baell J.B., Huang D.C. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 2002, 64:851-863.
191. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
192. Wang G., Nikolovska-Coleska Z., Yang C.Y., Wang R., Tang G., Guo J., Shangary S., Qiu S., Gao W., Yang D., Meagher J., Stuckey J., Krajewski K., Jiang S., Roller P.P., Abaan H.O., Tomita Y., Wang S. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 2006, 49:6139-6142.
193. Tang G., Nikolovska-Coleska Z., Qiu S., Yang C.Y., Guo J., Wang S. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. J. Med. Chem. 2008, 51:717-720.
194. Paoluzzi L., Gonen M., Gardner J.R., Mastrella J., Yang D., Holmlund J., Sorensen M., Leopold L., Manova K., Marcucci G., Heaney M.L., O'Connor O.A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008, 111:5350-5358.
195. Arnold A.A., Aboukameel A., Chen J., Yang D., Wang S., Al-Katib A., Mohammad R.M. Preclinical studies of apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol. Cancer 2008, 7:20.
196. Wei J., Stebbins J.L., Kitada S., Dash R., Zhai D., Placzek W.J., Wu B., Rega M.F., Zhang Z., Barile E., Yang L., Dahl R., Fisher P.B., Reed J.C., Pellecchia M. An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins. Front. Oncol. 2011, 1:28.
197. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., Goulet D., Viallet J., Belec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R.W., Beauparlant P., Shore G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19512-19517.
198. Perez-Galan P., Roue G., Villamor N., Campo E., Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-4449.
199. Shore G.C., Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology Am. Soc. Hematol. Educ. Program 2005, 226-230.
200. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009, 16:360-367.
201. Espona-Fiedler M., Soto-Cerrato V., Hosseini A., Lizcano J.M., Guallar V., Quesada R., Gao T., Perez-Tomas R. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochem. Pharmacol. 2012, 83:489-496.
202. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
203. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
204. Bruncko M., Oost T.K., Belli B.A., Ding H., Joseph M.K., Kunzer A., Martineau D., McClellan W.J., Mitten M., Ng S.C., Nimmer P.M., Oltersdorf T., Park C.M., Petros A.M., Shoemaker A.R., Song X., Wang X., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H., Elmore S.W. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 2007, 50:641-662.
205. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., Kelly P.N., Ekert P.G., Metcalf D., Roberts A.W., Huang D.C., Kile B.T. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
206. Josefsson E.C., James C., Henley K.J., Debrincat M.A., Rogers K.L., Dowling M.R., White M.J., Kruse E.A., Lane R.M., Ellis S., Nurden P., Mason K.D., O'Reilly L.A., Roberts A.W., Metcalf D., Huang D.C., Kile B.T. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J. Exp. Med. 2011, 208:2017-2031.
207. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., Huang D.C., Hymowitz S.G., Jin S., Khaw S.L., Kovar P.J., Lam L.T., Lee J., Maecker H.L., Marsh K.C., Mason K.D., Mitten M.J., Nimmer P.M., Oleksijew A., Park C.H., Park C.M., Phillips D.C., Roberts A.W., Sampath D., Seymour J.F., Smith M.L., Sullivan G.M., Tahir S.K., Tse C., Wendt M.D., Xiao Y., Xue J.C., Zhang H., Humerickhouse R.A., Rosenberg S.H., Elmore S.W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
208. Touzeau C., Dousset C., Le Gouill S., Sampath D., Leverson J.D., Souers A.J., Maiga S., Bene M.C., Moreau P., Pellat-Deceunynck C., Amiot M. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014, 28:210-212.
209. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
210. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., Verhaegen M., Soengas M., Ruvolo V.R., McQueen T., Schober W.D., Watt J.C., Jiffar T., Ling X., Marini F.C., Harris D., Dietrich M., Estrov Z., McCubrey J., May W.S., Reed J.C., Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
211. Anderson M.A., Huang D., Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin. Hematol. 2014, 51:219-227.
212. Wilson W.H., O'Connor O.A., Czuczman M.S., LaCasce A.S., Gerecitano J.F., Leonard J.P., Tulpule A., Dunleavy K., Xiong H., Chiu Y.L., Cui Y., Busman T., Elmore S.W., Rosenberg S.H., Krivoshik A.P., Enschede S.H., Humerickhouse R.A. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010, 11:1149-1159.
213. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., Carney D.A., He S.Z., Huang D.C., Xiong H., Cui Y., Busman T.A., McKeegan E.M., Krivoshik A.P., Enschede S.H., Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012, 30:488-496.
214. Vaillant F., Merino D., Lee L., Breslin K., Pal B., Ritchie M.E., Smyth G.K., Christie M., Phillipson L.J., Burns C.J., Mann G.B., Visvader J.E., Lindeman G.J. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013, 24:120-129.
215. Peirs S., Matthijssens F., Goossens S., Van de Walle I., Ruggero K., de Bock C.E., Degryse S., Cante-Barrett K., Briot D., Clappier E., Lammens T., De Moerloose B., Benoit Y., Poppe B., Meijerink J.P., Cools J., Soulier J., Rabbitts T.H., Taghon T., Speleman F., Van Vlierberghe P. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 2014, 124:3738-3747.
216. Ko T.K., Chuah C.T., Huang J.W., Ng K.P., Ong S.T. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 2014, 5:9033-9038.
217. Mattoo A.R., Zhang J., Espinoza L.A., Jessup J.M. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics. Clin. Cancer Res. 2014, 20:5446-5455.
218. Davids M.S., Seymour J.F., Gerecitano J.F., Kahl B.S., Pagel J.M., Wierda W.G., Anderson M.-A., Rudersdorf N.K., Gressick L.A., Montalvo N.P., Yang J., Busman T.A., Dunbaar M., Cerri E., Enschede S.H., Humerickhouse R.A., Roberts A.W. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood 2013, 122. (Abstract 1789).
219. Seymour J.F., Davids M.S., Pagel J.M., Kahl B.S., Wierda W.G., Miller T.P., Gerecitano J.F., Kipps T.J., Anderson M.-A., Huang D.C.S., Rudersdorf N.K., Gressick L.A., Montalvo N.P., Yang J., Busman T.A., Dunbar M., Cerri E., Enschede S.H., Humerickhouse R.A., Roberts A.W. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphoma leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 2013, 122. (Abstract 872).
220. Roberts A.W., Ma S., Brander D.M., Kipps T.J., Barrientos J.C., Davids M.S., Anderson M.-A., Tam C., Mason-Bright T., Rudersdorf N.K., Gressick L.A., Yang J., Munasinghe W., Zhu M., Cerri E., Enschee S.H., Humerickhouse R.A., Seymour J.F. Determination of recommended phase 2 dose OF ABT-199 (GDC-0199) combined with rituximab® in patients with relapse/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood 2014, 124. (Abstract 325).
221. Flinn I., Brunvand M., Dyer M.J.S., Hillman P., Jones J., Lymp J., Elhamy M., Vosganian G., Huang J., Kipps T.J. Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood 2014, 124. (Abstract 4687).
222. Salles G.A., Boyd T.E., Morschhauser F., Wendtner C.-M., Lymp J., Hilger J., Vosganian G., Huang J., Stilgenbauer S. Preliminary results of a phase 1b study (GO28440) combining GDC-0199 (ABT-199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood 2014, 124. (Abstract 3337).
223. de Vos S., Flowers C.R., Wang D., Swinnen L.J., Fowler N., Reid E., Gifford M., D'Amico D., Dunbar M., Zhu M., Yang J., Enschede S.H., Ricker J.L., Chien D., Humerickhouse R.A., Kozloff M. The BCL-2 inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Blood 2014, 124. (Abstract 1722).
224. Grover R., Wilson G.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 1996, 22:347-349.
225. Jiang S.X., Sato Y., Kuwao S., Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol. 1995, 177:135-138.
226. Joensuu H., Pylkkanen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 1994, 145:1191-1198.
227. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T., Tu S.M., Campbell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992, 52:6940-6944.
228. Sinicrope F.A., Hart J., Michelassi F., Lee J.J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1995, 1:1103-1110.
229. Gazzaniga P., Gradilone A., Vercillo R., Gandini O., Silvestri I., Napolitano M., Albonici L., Vincenzoni A., Gallucci M., Frati L., Agliano A.M. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int. J. Cancer 1996, 69:100-104.
230. Singh R., Saini N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis-a combined computational and experimental approach. J. Cell Sci. 2012, 125:1568-1578.
231. Kuwano Y., Nishida K., Kajita K., Satake Y., Akaike Y., Fujita K., Kano S., Masuda K., Rokutan K. Transformer 2beta and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA. Cell Death Differ 2015, 22:815-825.
232. Castilla C., Congregado B., Chinchon D., Torrubia F.J., Japon M.A., Saez C. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006, 147:4960-4967.
233. Keitel U., Scheel A., Thomale J., Halpape R., Kaulfuss S., Scheel C., Dobbelstein M. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget 2014, 5:11778-11791.
234. Shimizu S., Takehara T., Hikita H., Kodama T., Miyagi T., Hosui A., Tatsumi T., Ishida H., Noda T., Nagano H., Doki Y., Mori M., Hayashi N. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol. 2010, 52:698-704.
235. Zhan M., Qu Q., Wang G., Zhou H. Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL. Pharmazie 2013, 68:955-961.
236. Chen Y., Jacamo R., Konopleva M., Garzon R., Croce C., Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J. Clin. Invest. 2013, 123:2395-2407.
237. Guo R., Wang Y., Shi W.Y., Liu B., Hou S.Q., Liu L. MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules 2012, 17:14733-14747.
238. Nakano H., Miyazawa T., Kinoshita K., Yamada Y., Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int. J. Cancer 2010, 127:1072-1080.
239. Gutierrez-Castellanos S., Cruz M., Rabelo L., Godinez R., Reyes-Maldonado E., Riebeling-Navarro C. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Eur. J. Haematol. 2004, 72:231-238.
240. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., Wang H.G., Zhang X., Bullrich F., Croce C.M., Rai K., Hines J., Reed J.C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998, 91:3379-3389.
241. Quinn B.A., Dash R., Azab B., Sarkar S., Das S.K., Kumar S., Oyesanya R.A., Dasgupta S., Dent P., Grant S., Rahmani M., Curiel D.T., Dmitriev I., Hedvat M., Wei J., Wu B., Stebbins J.L., Reed J.C., Pellecchia M., Sarkar D., Fisher P.B. Targeting Mcl-1 for the therapy of cancer. Expert Opin. Investig. Drugs 2011, 20:1397-1411.
242. Wuilleme-Toumi S., Robillard N., Gomez P., Moreau P., Le Gouill S., Avet-Loiseau H., Harousseau J.L., Amiot M., Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252.
243. Zhuang L., Lee C.S., Scolyer R.A., McCarthy S.W., Zhang X.D., Thompson J.F., Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 2007, 20:416-426.
244. Ding Q., He X., Xia W., Hsu J.M., Chen C.T., Li L.Y., Lee D.F., Yang J.Y., Xie X., Liu J.C., Hung M.C. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007, 67:4564-4571.
245. Shigemasa K., Katoh O., Shiroyama Y., Mihara S., Mukai K., Nagai N., Ohama K. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn. J. Cancer Res. 2002, 93:542-550.
246. Backus H.H., van Riel J.M., van Groeningen C.J., Vos W., Dukers D.F., Bloemena E., Wouters D., Pinedo H.M., Peters G.J. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann. Oncol. 2001, 12:779-785.
247. Likui W., Qun L., Wanqing Z., Haifeng S., Fangqiu L., Xiaojun L. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J. Surg. Oncol. 2009, 100:396-400.
248. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., Bodingbauer M., Crevenna R., Monia B.P., Peck-Radosavljevic M., Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 2006, 44:151-157.
249. Steele R., Mott J.L., Ray R.B. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010, 1:381-387.
250. Schwickart M., Huang X., Lill J.R., Liu J., Ferrando R., French D.M., Maecker H., O'Rourke K., Bazan F., Eastham-Anderson J., Yue P., Dornan D., Huang D.C., Dixit V.M. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-107.
251. Gong J., Zhang J.P., Li B., Zeng C., You K., Chen M.X., Yuan Y., Zhuang S.M. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013, 32:3071-3079.
252. Crawford M., Batte K., Yu L., Wu X., Nuovo G.J., Marsh C.B., Otterson G.A., Nana-Sinkam S.P. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 2009, 388:483-489.
253. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., Helgason E., Ernst J.A., Eby M., Liu J., Belmont L.D., Kaminker J.S., O'Rourke K.M., Pujara K., Kohli P.B., Johnson A.R., Chiu M.L., Lill J.R., Jackson P.K., Fairbrother W.J., Seshagiri S., Ludlam M.J., Leong K.G., Dueber E.C., Maecker H., Huang D.C., Dixit V.M. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
254. Inuzuka H., Fukushima H., Shaik S., Liu P., Lau A.W., Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011, 2:239-244.
255. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.-M., Yang-Yen H.-F., Karras J., Jove R., Loughran T.P. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 2001, 107:351-362.
256. Lee H.W., Lee S.S., Lee S.J., Um H.D. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res. 2003, 63:1093-1100.
257. Pritchard D.M., Print C., O'Reilly L., Adams J.M., Potten C.S., Hickman J.A. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 2000, 19:3955-3959.
258. Wilson J.W., Nostro M.C., Balzi M., Faraoni P., Cianchi F., Becciolini A., Potten C.S. Bcl-w expression in colorectal adenocarcinoma. Br. J. Cancer 2000, 82:178-185.
259. Hoelzinger D.B., Mariani L., Weis J., Woyke T., Berens T.J., McDonough W.S., Sloan A., Coons S.W., Berens M.E. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005, 7:7-16.
260. Lee W.S., Woo E.Y., Kwon J., Park M.J., Lee J.S., Han Y.H., Bae I.H. Bcl-w enhances mesenchymal changes and invasiveness of glioblastoma cells by inducing nuclear accumulation of beta-catenin. PLoS One 2013, 8:e68030.
261. Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A., Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004, 64:1403-1410.
262. Valdez B.C., Murray D., Ramdas L., de Lima M., Jones R., Kornblau S., Betancourt D., Li Y., Champlin R.E., Andersson B.S. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk. Res. 2008, 32:1684-1697.
263. Cao J., Cai J., Huang D., Han Q., Yang Q., Li T., Ding H., Wang Z. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol. Rep. 2013, 30:701-706.
264. Xu Y., Zhao F., Wang Z., Song Y., Luo Y., Zhang X., Jiang L., Sun Z., Miao Z., Xu H. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene 2012, 31:1398-1407.
265. Shen L., Li J., Xu L., Ma J., Li H., Xiao X., Zhao J., Fang L. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp. Ther. Med. 2012, 3:475-480.
266. Bo J., Yang G., Huo K., Jiang H., Zhang L., Liu D., Huang Y. microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J. 2011, 278:786-792.
267. Lin C.J., Gong H.Y., Tseng H.C., Wang W.L., Wu J.L. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 375:315-320.
268. Lapham A., Adams J.E., Paterson A., Lee M., Brimmell M., Packham G. The Bcl-w promoter is activated by beta-catenin/TCF4 in human colorectal carcinoma cells. Gene 2009, 432:112-117.
269. Nagy B., Lundan T., Larramendy M.L., Aalto Y., Zhu Y., Niini T., Edgren H., Ferrer A., Vilpo J., Elonen E., Vettenranta K., Franssila K., Knuutila S. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br. J. Haematol. 2003, 120:434-441.
270. Mahadevan D., Spier C., Della Croce K., Miller S., George B., Riley C., Warner S., Grogan T.M., Miller T.P. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol. Cancer Ther. 2005, 4:1867-1879.
271. Piva R., Pellegrino E., Mattioli M., Agnelli L., Lombardi L., Boccalatte F., Costa G., Ruggeri B.A., Cheng M., Chiarle R., Palestro G., Neri A., Inghirami G. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J. Clin. Invest. 2006, 116:3171-3182.
272. Morales A.A., Olsson A., Celsing F., Osterborg A., Jondal M., Osorio L.M. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int. J. Cancer 2005, 113:730-737.
273. Kucharczak J.F., Simmons M.J., Duckett C.S., Gelinas C. Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ. 2005, 12:1225-1239.
274. Herold M.J., Zeitz J., Pelzer C., Kraus C., Peters A., Wohlleben G., Berberich I. The stability and anti-apoptotic function of A1 are controlled by its C terminus. J. Biol. Chem. 2006, 281:13663-13671.
275. Zong W.X., Edelstein L.C., Chen C., Bash J., Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999, 13:382-387.
276. Morgan R.K., Kingham P.J., Walsh M.T., Curran D.R., Durcan N., McLean W.G., Costello R.W. Eosinophil adhesion to cholinergic IMR-32 cells protects against induced neuronal apoptosis. J. Immunol. 2004, 173:5963-5970.
277. Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012, 19:67-74.
278. Krajewska M., Kitada S., Winter J.N., Variakojis D., Lichtenstein A., Zhai D., Cuddy M., Huang X., Luciano F., Baker C.H., Kim H., Shin E., Kennedy S., Olson A.H., Badzio A., Jassem J., Meinhold-Heerlein I., Duffy M.J., Schimmer A.D., Tsao M., Brown E., Sawyers A., Andreeff M., Mercola D., Krajewski S., Reed J.C. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin. Cancer Res. 2008, 14:3011-3021.
279. van de Kooij B., Rooswinkel R.W., Kok F., Herrebout M., de Vries E., Paauwe M., Janssen G.M., van Veelen P.A., Borst J. Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B. Oncogene 2013, 32:5439-5448.
280. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., Huang D.C., Hymowitz S.G., Jin S., Khaw S.L., Kovar P.J., Lam L.T., Lee J., Maecker H.L., Marsh K.C., Mason K.D., Mitten M.J., Nimmer P.M., Oleksijew A., Park C.H., Park C.M., Phillips D.C., Roberts A.W., Sampath D., Seymour J.F., Smith M.L., Sullivan G.M., Tahir S.K., Tse C., Wendt M.D., Xiao Y., Xue J.C., Zhang H., Humerickhouse R.A., Rosenberg S.H., Elmore S.W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
281. Becattini B., Kitada S., Leone M., Monosov E., Chandler S., Zhai D., Kipps T.J., Reed J.C., Pellecchia M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem. Biol. 2004, 11:389-395.
282. Zeitlin B.D., Joo E., Dong Z., Warner K., Wang G., Nikolovska-Coleska Z., Wang S., Nor J.E. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res. 2006, 66:8698-8706.